Glycosidases, including b-D-galactosidase and b-D-glucosidase, are involved in a range of metabolic disorders, such as cancer, viral or bacterial infections, and diabetes. Previously, we scanned the pharmacophoric space of these enzymes and had a self-consistent and predictive quantitative structure-activity relationship that was used to identify several b-D-galactosidase and b-D-glucosidase inhibitors via in silico search of structural databases. Guided by the preceding modeling efforts, synthesis of a series of tryptophan and thiosemicarbazide derivatives as b-Dgalactosidase and b-D-glucosidase inhibitors that match the generated pharmacophores followed by in vitro bioassay was carried out. Synthesized compounds 3c (37 % inhibition at 100 lM) and 4d (49 % inhibition at 100 lM) exhibited the best inhibitory bioactivities against b-Dgalactosidase and b-D-glucosidase, respectively. They can serve as a promising lead compounds for the development of potential glycosidase inhibitors.